CD274 and melanoma: Despite the mechanism of immunotherapy resistance mediated by exosomal-PD-L1 is still under investigation, studies suggest that it can significantly inhibit the activation of cytotoxic T cells in melanoma, breast cancer and head and neck cancer patients, negatively affecting the response to anti-PD1 antibody (76).